Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325 – Optimum Strategic Communications
Summary
Investment will support investigation of Missions small molecule drug MTX325 in patients with early-stage Parkinsons disease Marks latest step in Missions relationship with The Michael J. Fox Foundation (MJFF), after MJFF awarded Mission preclinical research grants in 2017 and 2021, and first with Parkinsons UK Comes as promising early data from healthy volunteers show MTX325 has a good safety profile, pharmacokinetics and CNS penetrationCambridge, UK 02 July 2024 Mission Therapeutics (Mission or the Company), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinsons Research (MJFF) and Parkinsons UK. The funding will help advance Missions potential disease-modifying treatment for Parkinsons, MTX325.